CureVac N.V. (CVAC)
NASDAQ: CVAC
· Real-Time Price · USD
5.38
-0.06 (-1.10%)
At close: Jun 23, 2025, 3:59 PM
5.36
-0.46%
Pre-market: Jun 24, 2025, 08:22 AM EDT
-1.10% (1D)
| Bid | 5.25 |
| Market Cap | 1.21B |
| Revenue (ttm) | 535.18M |
| Net Income (ttm) | 162.19M |
| EPS (ttm) | 0.92 |
| PE Ratio (ttm) | 5.85 |
| Forward PE | -10.66 |
| Analyst | Buy |
| Ask | 5.37 |
| Volume | 723,982 |
| Avg. Volume (20D) | 1,155,101 |
| Open | 5.40 |
| Previous Close | 5.44 |
| Day's Range | 5.37 - 5.42 |
| 52-Week Range | 2.37 - 5.72 |
| Beta | 2.49 |
About CVAC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CVAC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CVAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
CureVac N.V. is scheduled to release its earnings on Aug 14, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+37.59%
CureVac shares are trading higher after BioNTech a...
Unlock content with
Pro Subscription
1 month ago
+10.59%
CureVac shares are trading higher following Q1 reported financial results.
1 week ago · proactiveinvestors.com
BioNTech boosts cancer mRNA pipeline with CureVac acquisitionBioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...
